title: Oral mucosal side effects of cytotoxic chemotherapy of testicular cancer. A retrospective study.
abstract: Cancer chemotherapy often leads to injury of normal cells. Adverse effects on oral mucosa have been documented for several cytotoxic treatment regimens. The aim of the present retrospective study was to evaluate incidence and degree of oral soft tissue side-effects of a cisplatin-based chemotherapy regimen used for treating testicular cancer. The study was based upon a questionnaire mailed to 56 consecutive patients treated at the Norwegian Radium Hospital. A total of 39 individuals joined the study, as 2 patients refused and 15 did not reply. The patients were divided into two groups, a case group (24 individuals) having received 4 7 cycles of cisplatin-based chemotherapy in addition to surgery, and a control group (15 individuals) treated with surgery alone. The study revealed that 62% of the patients in the chemotherapy group developed adverse soft tissue reactions, with mucositis and pain as chief complaints, whereas none in the control group experienced any mucosal complications.
authors.affiliation: Department of Oral Surgery and Oral Medicine, Faculty of Dentistry, University of Oslo, Norway. brokstad@odont.uio.no
authors.forename: B B
authors.initials: BB
authors.lastname: Herlofson
authors.forename: K
authors.initials: K
authors.lastname: Norman-Pedersen
authors.forename: M
authors.initials: M
authors.lastname: Redfors
authors.forename: S D
authors.initials: SD
authors.lastname: Fosså
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D001768:Blister / Q000139:chemically induced; D016022:Case-Control Studies; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D015994:Incidence; D008297:Male; D009059:Mouth Diseases / Q000139:chemically induced*; D009061:Mouth Mucosa / Q000187:drug effects*; D019226:Oral Ulcer / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced; D012189:Retrospective Studies; D013280:Stomatitis / Q000139:chemically induced; D011795:Surveys and Questionnaires; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000601:surgery; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide